209 related articles for article (PubMed ID: 20142396)
1. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Schenk JM; Kristal AR; Neuhouser ML; Tangen CM; White E; Lin DW; Kratz M; Thompson IM
Am J Epidemiol; 2010 Mar; 171(5):571-82. PubMed ID: 20142396
[TBL] [Abstract][Full Text] [Related]
2. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Kristal AR; Schenk JM; Song Y; Arnold KB; Neuhouser ML; Goodman PJ; Lin DW; Stanczyk FZ; Thompson IM
Am J Epidemiol; 2008 Dec; 168(12):1416-24. PubMed ID: 18945688
[TBL] [Abstract][Full Text] [Related]
3. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
Schenk JM; Kristal AR; Neuhouser ML; Tangen CM; White E; Lin DW; Thompson IM
Prostate; 2009 Sep; 69(12):1303-11. PubMed ID: 19475640
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.
Neuhouser ML; Schenk J; Song YJ; Tangen CM; Goodman PJ; Pollak M; Penson DF; Thompson IM; Kristal AR
Prostate; 2008 Sep; 68(13):1477-86. PubMed ID: 18618736
[TBL] [Abstract][Full Text] [Related]
5. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Schenk JM; Calip GS; Tangen CM; Goodman P; Parsons JK; Thompson IM; Kristal AR
Am J Epidemiol; 2012 Jul; 176(2):156-63. PubMed ID: 22759721
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
Kristal AR; Price DK; Till C; Schenk JM; Neuhouser ML; Ockers S; Lin DW; Thompson IM; Figg WD
Prostate; 2010 May; 70(6):584-90. PubMed ID: 19938041
[TBL] [Abstract][Full Text] [Related]
7. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.
Schenk JM; Kristal AR; Arnold KB; Tangen CM; Neuhouser ML; Lin DW; White E; Thompson IM
Am J Epidemiol; 2011 Jun; 173(12):1419-28. PubMed ID: 21540324
[TBL] [Abstract][Full Text] [Related]
8. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Kristal AR; Arnold KB; Schenk JM; Neuhouser ML; Goodman P; Penson DF; Thompson IM
Am J Epidemiol; 2008 Apr; 167(8):925-34. PubMed ID: 18263602
[TBL] [Abstract][Full Text] [Related]
9. Cytokine variations in patients with hormone treated prostate cancer.
Wise GJ; Marella VK; Talluri G; Shirazian D
J Urol; 2000 Sep; 164(3 Pt 1):722-5. PubMed ID: 10953133
[TBL] [Abstract][Full Text] [Related]
10. Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Breyer BN; Huang WY; Rabkin CS; Alderete JF; Pakpahan R; Beason TS; Kenfield SA; Mabie J; Ragard L; Wolin KY; Grubb RL; Andriole GL; Sutcliffe S
BJU Int; 2016 Jan; 117(1):145-54. PubMed ID: 25601300
[TBL] [Abstract][Full Text] [Related]
11. Microwave thermotherapy for benign prostatic hyperplasia.
Hoffman RM; Monga M; Elliott SP; Macdonald R; Langsjoen J; Tacklind J; Wilt TJ
Cochrane Database Syst Rev; 2012 Sep; (9):CD004135. PubMed ID: 22972068
[TBL] [Abstract][Full Text] [Related]
12. Increased serum soluble tumor necrosis factor receptor levels are associated with insulin resistance in liver cirrhosis.
Lin SY; Wang YY; Sheu WH
Metabolism; 2004 Jul; 53(7):922-6. PubMed ID: 15254888
[TBL] [Abstract][Full Text] [Related]
13. Does Inflammation Mediate the Obesity and BPH Relationship? An Epidemiologic Analysis of Body Composition and Inflammatory Markers in Blood, Urine, and Prostate Tissue, and the Relationship with Prostate Enlargement and Lower Urinary Tract Symptoms.
Fowke JH; Koyama T; Fadare O; Clark PE
PLoS One; 2016; 11(6):e0156918. PubMed ID: 27336586
[TBL] [Abstract][Full Text] [Related]
14. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Kristal AR; Arnold KB; Schenk JM; Neuhouser ML; Weiss N; Goodman P; Antvelink CM; Penson DF; Thompson IM
J Urol; 2007 Apr; 177(4):1395-400; quiz 1591. PubMed ID: 17382740
[TBL] [Abstract][Full Text] [Related]
15. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
[TBL] [Abstract][Full Text] [Related]
16. Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort.
Grote VA; Kaaks R; Nieters A; Tjønneland A; Halkjær J; Overvad K; Skjelbo Nielsen MR; Boutron-Ruault MC; Clavel-Chapelon F; Racine A; Teucher B; Becker S; Pischon T; Boeing H; Trichopoulou A; Cassapa C; Stratigakou V; Palli D; Krogh V; Tumino R; Vineis P; Panico S; Rodríguez L; Duell EJ; Sánchez MJ; Dorronsoro M; Navarro C; Gurrea AB; Siersema PD; Peeters PH; Ye W; Sund M; Lindkvist B; Johansen D; Khaw KT; Wareham N; Allen NE; Travis RC; Fedirko V; Jenab M; Michaud DS; Chuang SC; Romaguera D; Bueno-de-Mesquita HB; Rohrmann S
Br J Cancer; 2012 May; 106(11):1866-74. PubMed ID: 22617158
[TBL] [Abstract][Full Text] [Related]
17. Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia.
Khan S; Wolin KY; Pakpahan R; Grubb RL; Colditz GA; Ragard L; Mabie J; Breyer BN; Andriole GL; Sutcliffe S
BMC Urol; 2021 Mar; 21(1):47. PubMed ID: 33773592
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
[TBL] [Abstract][Full Text] [Related]
19. Soluble cytokine receptors in renal vasculitis and lupus nephritis.
Tesar V; Jirsa M; Zima T; Kalousová M; Bartunková J; Stejskalová A; Dostál C; Zabka J
Med Sci Monit; 2002 Jan; 8(1):BR24-9. PubMed ID: 11782670
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men.
Meigs JB; Mohr B; Barry MJ; Collins MM; McKinlay JB
J Clin Epidemiol; 2001 Sep; 54(9):935-44. PubMed ID: 11520654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
